The US has a law requiring clinical trial results to be made public with a $10,000/day fine for breaking it. Despite poor adherence, the FDA has never collected.
I wrote for @DKThomp’s newsletter on what AI actually needs to cure disease (and the boring policy answers)
@Jabaluck@JulianDJacobs recently put out a cool paper about (2) — interestingly, the holdouts were about as common among low-income workers (21%) as high-income ones (22%)
Looking forward to judging for this — there’s not nearly enough thinking about how AI will impact low- and middle-income countries out there. Submit if you have thoughts!
There’s a lot of writing on what AI means for rich-country economies and far less on what it means for Nairobi, Lagos or Lima.
@asteriskmgzn and @indevmag want to fix that. Essay contest: $10k first prize, deadline Dec 31.
https://t.co/5YCG2mxDQM
I'm hiring 2-3 Associate Program Officers or Research Fellows for my team at Coefficient Giving.
The job involves grant-making and research on AI x global health and development. We're aiming to spend ~$100M in the next year, on questions ranging from how LMICs can grow if AI eats the export-services path, to whether AI-read TB X-rays work in clinics without a radiologist.
Apply here by Oct 4 if it sounds interesting: https://t.co/eX4Ai06jXz
Totally agree these are neglected questions!
We recently put out an RFP (which closed a few weeks ago) on this and other topics - https://t.co/QwMLtyMdNN
And I write about these questions in a personal capacity here - https://t.co/a7DlMxQvbO
Always interested in hearing about what people think is missing in the field / should be funded
Unfortunately, I suspect the default path for AI's impact on developing countries is divergence, and not convergence, with rich ones - good piece on this in @ReadTransformer
Transformative AI could supercharge development for the world’s poorest countries
But only if governments act fast to lay groundwork that spreads AI’s gains rather than concentrating them, writes @FutureEconJacob ✍️
https://t.co/7j8YWufAyX
We started a Substack! https://t.co/rIyENXnfKU
One of my favorite things about working at @coeff_giving is how much good public writing our staff produces. A few of my favorites from the past year:
1️⃣ @Lewis_Bollard's great end-of-year newsletter on big wins for farmed animals:
https://t.co/PsNjEl0o8K
2️⃣ @deenamousa on why there aren't more AI radiologists, in @WorksInProgMag:
https://t.co/bp1xfCkdUs
3️⃣ Andrew Snyder-Beattie on four pillars for countering catastrophic biological risk, from our biosecurity team's new blog:
https://t.co/aHv1U3AfcF
None of those are on our website, so you would've had to know where to look. Now, posts like that will all be in one place.
The US has a law requiring clinical trial results to be made public with a $10,000/day fine for breaking it. Despite poor adherence, the FDA has never collected.
I wrote for @DKThomp’s newsletter on what AI actually needs to cure disease (and the boring policy answers)
Unfortunately most of these recommendations end up having a flavor of giving up on building a growth engine at home and buying a small stake in growth that happens elsewhere, whether via attracting tourists or remittances. I hope I'm wrong.
Full piece: https://t.co/IpVi7Zb4qd
NEW: If AI erodes paths to growth, like manufacturing and service exports, what can poor countries do?
I went through commonly-recommended contenders and came out skeptical that any are a truly comparable growth engine. Is sending people to rich countries the best bet?
This is, of course, sensitive to not only demand but also the politics of migration. And remittances aren't the same as a growing domestic industry; they mostly fund consumption and housing.